Revvity (RVTY) announced that it received 510(k) clearance from the FDA for Euroimmun’s automated chemiluminescence-based immunoassay test for free testosterone.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVTY:
- Revvity downgraded to Market Perform from Outperform at Bernstein
- Revvity price target lowered to $125 from $134 at Evercore ISI
- Revvity upgraded to Buy from Neutral at BofA
- Revvity price target lowered to $135 from $140 at Barclays
- Revvity broadens deal with Genomics England to advance genomics in UK